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ABSTRACT
In this study, RNA interference (RNAi) was carried out as an experimental technique to knockdown three mitogen-activated 
protein kinase (MAPK) pathway genes, raf-1, mekk1 and mlk3 in acute myeloid leukemia (AML) cells. Conventionally, RNAi 
knockdown experiments target a single gene for functional studies or therapeutic purposes. We wanted to explore the 
potential differences or similarities between targeting single targets or multiple target genes in a single application. We 
achieved knockdown of gene expression levels of between 40 and 60% for the RNAi experiments, with better knockdown 
observed in single target gene experiments in comparison with the multiple target gene experiment. Microarray analysis 
indicated that the transfection process had most likely induced the immune response from the cells in every RNAi treatment. 
This might indicate that when the MAPK signaling pathway is partially blocked, in tandem with the immune response, 
the cells will begin signaling for apoptosis leading to cellular death of the leukemic cells.
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ABSTRAK
Dalam kajian ini, penggangguan RNA (RNAi) digunakan sebagai teknik uji kaji untuk menurunkan tiga gen protein kinase 
diaktifkan-mitogen (MAPK) iaitu gen raf1, mekk1 dan mlk3 di dalam sel mieloid leukemia akut (AML). Kebiasaannya, 
eksperimen RNAi dijalankan untuk menyasar satu gen sahaja demi mengkaji fungsi atau peranan terapi. Kami telah 
mengkaji potensi perbezaan atau persamaan antara menyasar satu atau lebih gen dalam satu aplikasi. Kami berjaya 
mencapai penurunan pengekspresan gen daripada 40% hingga 60% dan RNAi kelihatan lebih berkesan melalui 
penyasaran satu gen. Analisis mikroatur menunjukkan bahawa proses transfeksi kemungkinan tinggi telah mengaruh 
tindak balas imun dalam setiap perlakuan RNAi yang telah dilakukan. Ini mungkin memberi petunjuk bahawa apabila 
pengisyaratan tapak jalan MAPK dihalang separa, disertakan pengaruhan tindak balas imun, tapak laluan apoptosis 
akan dimulakan dan mengakibatkan kematian sel kepada sel-sel leukemia.
Kata kunci: Mieloid leukemia akut; penggangguan RNA; tapak jalan MAPK; tindak balas imun
INTRODUCTION
Acute myeloid leukaemia (AML) is a type of blood 
cancer resulting from an abnormal proliferation of 
myeloid cells in the bone marrow. Recent advancement 
in the understanding of the molecular basis in AML has 
brought more focus towards identification of novel 
and specific therapeutic targets (Tallman et al. 2005). 
Molecular markers that show up in AML are evident on 
the cytogenetic level and in certain oncogenes (Gregory 
et al. 2009; Haferlach 2008). Isolated mutations do not 
lead directly to AML, it requires a cooperating mutation 
to progress to AML and the combination varies from 
patient to patient (Kim et al. 2008). There are 3 classes 
of mutations in AML (Haferlach 2008). The first class 
interferes with differentiation and locks the cell progress. 
In the second class of mutation, activating mutations 
increase cell proliferation and the third class mutation 
affects genes that are involved in cell cycle regulation or 
apoptosis. The second class mutation such as the Fms-
like tyrosine kinase 3 (FLT3) mutation normally leads 
to activation of signal transduction pathways such as the 
MAPK pathway (Towatari et al. 1997). 
 It has been suggested that by blocking the MAPK 
pathway at strategic points, we could also block 
abnormal cell proliferation (Sebolt-Leopold et al. 
1999). One target of interest is raf1, a map3k gene of 
the extracellular signal-regulated kinase 1 / 2 (ERK 1 / 2) 
pathway downstream of the ras gene and associated with 
proliferative and anti-apoptotic properties in cells. Studies 
on raf1’s role in cancers have revealed that when it is 
inhibited, the cells would stop proliferating and undergo 
apoptosis (Alejandro & Johnson 2008; Weissinger et al. 
1997) and when the inhibitor is removed or the loss of 
the raf1 kinase inhibitor (rkip) has occurred, this would 
lead to tumour progression (Minoo et al. 2007). Another 
strong candidate for RNAi knockdown is the mekk1 gene 
1132 
which is also a map3k gene but is involved in the c-Jun 
N-terminal kinase or stress-activated protein kinase (JNK 
/ SAPK) pathway (Gallagher et al. 2002). Expression of 
mekk1 has been reported to induce cell death through 
apoptosis and activates the p53 tumor suppressor gene 
(Fuchs et al. 1998). There have been contradicting reports 
where dominant negative mekk1 genotypes in pancreatic 
cancer cells can inhibit survival of the cells (Hirano et 
al. 2002). Su et al. (2009) have shown that the reduction 
of mekk1 expression can inhibit metastatic properties in 
pancreatic cancer cells. 
 Mlk3 is a map3k gene and reported to be a key 
regulator of the p38 /MAPK and JNK/SAPK pathway 
(Tibbles et al. 1996). Initially, mlk3 was suspected to be 
a specific activator of the JNK pathway that was activated 
by tumor necrosis factor (TNF) signaling (Brancho et al. 
2005). Mlk3 had been shown to be activated by the tumor 
necrosis factor (TNF) β, inducing apoptosis in cells via the 
p38 / MAPK pathway (Kim et al. 2004) and through TNF 
– α, where TRAF2, an adaptor protein on the cytoplasmic 
end of the TNF – α receptor, will associate with mlk3 to 
activate the JNK / SAPK pathway (Sondarva et al. 2010). 
Chadee and Kyriakis (2004) reported that when mlk3 
expression was silenced using RNAi, the mitogenic and 
cytokine activation of JNK, p38 and ERK pathways were 
all suppressed. Recently, Chen et al. (2010) reported 
high expression of mlk3 in the breast cancer cells and 
proceeded to show that mlk3 promotes the migrative and 
invasive properties of the breast cancer cells. An insight 
of raf1, mekk1 and mlk3 individual or combined functions 
in acute myeloid leukemia might prove to be invaluable 
to understanding its potential therapeutic value. 
 RNA interference (RNAi) is a naturally occuring 
post-transcriptional gene silencing mechanism which has 
the ability to transiently inhibit the translation of specific 
mRNA in cells (Fire et al. 1998). RNAi has been explored 
with interest in the potential benefits of the phenomenon, 
particularly in the treatment of human disease (Cheng et 
al. 2003; Kim & Rossi 2007). Further studies showed that 
RNAi leads to the sequence-specific silencing of a gene 
via the introduction of 21- 22 bp double-stranded RNA 
(dsRNA) (Elbashir et al. 2001), which are subsequently 
degraded by the cells (Zamore et al. 2000). RNAi-based 
therapy is still at an early stage and has many critical 
issues, mainly in delivery to target cells (Kim 2003), 
although there are ongoing clinical trials for RNAi, such 
as the siRNA-027 which was designed to treat age-related 
macular degeneration (AMD) demonstrating promising 
results in phase I of the trial (Whelan 2005). RNAi 
generates genuine clinical interest because it is a natural 
process which occurs in organisms and should not invoke 
an undesired response or cause baneful side effects (Hood 
2004). Hence, target-based therapies using RNAi hold 
promise for the development of novel treatment modalities 
for AML. To explore this possibility, we wanted to establish 
the effects of targeting raf1, mekk1 and mlk3 for RNAi at 
the gene expression level in the AML cell line model, U937 
and elucidate novel therapeutic targets or pathways.
MATERIALS AND METHODS
PREPARATION OF siRNA
The siRNA design was carried out using Block-IT RNAi 
designer (InvitrogenTM) and oligonucleotide synthesis 
was sourced from InvitrogenTM. Stealth Validated siRNA 
for the target genes raf1, mekk1 and mlk3 are 25-mer, 
double-stranded RNA which have been validated for 
specific knockdown and are suitable for transfection into 
mammalian cells without inducing antiviral or interferon 
response. Negative controls with different GC content, 
defined as low and high by Invitrogen were used against 
the siRNA for the target genes, with the raf1 and mekk1 
siRNA paired against the low GC negative control while 
mlk3 was paired against the high GC negative control. All 
siRNA were procured in a 20 μM stock concentration.
Invitrogen Validated Stealth siRNA sequences:
raf1:  5’ AAU AAG AGU UGU CUG AUG UUA CUC 
C 3’
 3’ UUA UUC UCA ACA GAC UAC AAU GAG 
G 5’
mekk1: 5’ UUU GAA GGC UCC AUA UUU ACU CAG 
C 3’
 3’ AAA CUU CCG AGG UAU AAA UGA GUC 
G 5’
mlk3: 5’ UAC ACC UUG CCA AAG CCU CCA AUG C 
3’
 3’ AUG UGG AAC GGU UUC GGA GGU UAC 
G 5’
 Sequences for the low and high GC negative siRNA 
controls and gapdh positive siRNA control were not 
disclosed by the supplier (InvitrogenTM).
CELL CULTURE AND TRANSFECTION
U937 cell line (Sundstrom & Nilsson 1976), an in vitro 
model for AML, was procured as a kind gift from the 
Institute of Medical Molecular Biotechnology (IMMB), 
Universiti Teknologi MARA Malaysia. The cell line was 
cultured in Rose Park Memorial Institute-1640 (RPMI-
1640) medium (Sigma-Aldrich Co.) with 10% fetal 
bovine serum (FBS) (PAA), 1% antibiotic/antimycotic 
(PAA) and 1% L-glutamine (PAA), in 75 cm2 tissue culture 
flasks (Corning Inc.) and 6-well plates (Corning Inc.) at 
37˚C in a CO2 incubator. In the experiments involving 
RNAi, the antibiotics was excluded from the complete 
medium. The siRNA was delivered into the cell line 
using GenomONETM–Neo ex, a hemagglutinating Virus 
of Japan (HVJ) envelope vector kit (Cosmo Bio Co. Ltd.) 
and carried out according to manufacturer’s protocol. A 
day before transfection, cells were prepared in a T75 flask 
with a confluency level of 50%. On the day of transfection, 
cells were reconstituted in fresh culture media without 
antibiotics to a concentration of 2 × 106 cells/mL and 
stored on ice before use. The optimal time and dosage 
for gene knockdown was determined between 24 and 48 
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h incubation period and transfection reagent dosage was 
tested between 0.25 AU and 0.50 AU (AU = Assay Units; 
Standard amount (40 μL) used for transfection with 
plasmid DNA, using a 6-well plate). Transfection efficiency 
was monitored with fluorescent oligonucleotides using a 
fluorescent microscope and gene expression knockdown 
effect was measured with reverse-transcription quantitative 
PCR (RT-qPCR).
RNA EXTRACTION AND CDNA SYNTHESIS
Cells were harvested and total RNA extracted after the 
incubation period. RNA extraction was carried out using 
RNeasy Protect Mini Kit according to manufacturer’s 
protocols. RNA quantity and quality was assessed with 
the Agilent Bioanalyzer and IMPLEN nanophotometer at 
wavelength of 260 nm (RNA concentration is 1 OD = 40 
ng/uL. The total RNA was extracted and then converted 
into cDNA using Quantitect Reverse Transcription Kit 
(QIAGEN) according to manufacturer’s protocols.
REAL-TIME QUANTITATIVE PCR AND GENECHIP HUMAN 
GENE 1.0 ST ARRAY ANALYSIS
Primers for raf1, mekk1, mlk3 and gapdh were designed 
and sourced through the Quantitect Primer Assay (QIAGEN). 
Real-time qPCR was carried out in the BioRad Chromo4 
Thermocycler using the QuantiFast SYBR Green Kit 
(QIAGEN) according to manufacturer protocols.
Quantitect Primer Assays: 
raf1 :  Assay name : Hs_RAF1_1_SG  
  Cat. No.: QT00038969
mekk1 :  Assay name : Hs_MAP3K1_1_SG  
  Cat. No.: QT00088998
mlk3 : Assay name : Hs_MAP3K11_1_SG  
  Cat. No.: QT00084749 
gapdh :  Assay name : Hs_GAPDH_2_SG  
  Cat. No.: QT01192646
 Total RNA was used to synthesize cDNA for the 
GeneChip Human Gene 1.0 ST Array through a two cycle 
step according to the manufacturer’s protocol (QIAGEN) 
and hybridized to the probes on the chip for 16 h in a 
hybridization oven. The chips were then washed and 
scanned using the Affymetrix washing and scanning 
stations. The quality of the hybridization signals was 
validated and data set exported for analysis in third-
party software, Genespring 11.5 GX (Agilent). Pathway 
analysis was done using the online software, Database 
for Annotation, Visualization and Integrated Discovery 
(D.A.V.I.D.) (Huang et al. 2009).
RESULTS AND DISCUSSION
CELL MORPHOLOGY AND RNAI KNOCKDOWN
To investigate the effects of RNAi knockdown in selected 
genes, we observed the morphology of the cells before 
and after transfection. We observed that the number of 
cells and the overall size of the cells are much larger at 
0 h of transfection compared to 24 h later, as shown in 
Figure 1. The cells appeared to undergone a regression in 
proliferation. This provided us an indication that the RNAi 
treatment has a negative effect on the cell’s capabilities to 
grow and compromised its capacity to survive. To validate 
that we had achieved proper knockdown, we carried out a 
reverse-transcription PCR to measure the expression levels 
of the target genes according to the applied treatment. 
The results are shown in Figure 2 and Table 1, where the 
genes that were targeted individually achieved knockdown 
levels of 50-60% and 40-50% for genes that were targeted 
together in the multiple target RNAi.
 We had optimized the parameters to allocate the 
mixture of three different siRNA in a single dosage 
application. We determined the optimal concentration 
for a single RNAi target treatment which we concluded 
as 0.5 Assay Unit (AU; Standard amount (40 μL) used 
FIGURE 1. U-937 cell line transfected with mix RNAi (containing raf1, mekk1 and mlk3 siRNA) in a 
single treatment observed under light microscopy (10 × 20 magnification) (a) At 0 h 
incubation period; (b) At 24 h incubation period
(a) (b)
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for transfection with plasmid DNA, using a 6-well plate) 
and then we tested out three different combinations to 
determine the best possible mixture as described in Table 
2. We were aware of the risks of off-target effects and 
interferon responses, hence we took as many steps as 
we could to minimize any technical errors which could 
lead to it, such as siRNA overdosage. The whole design 
of the mixed siRNA experiment appears fallible to this 
conclusion. When transfecting more than a single design of 
siRNA, there is always a possibility that either the siRNAs 
will randomly miss their target genes or if they do reach 
their target genes, they would not exhibit their maximum 
RNAi potential. We had to ensure that any observable 
phenotypic or gene expression profile that was produced 
by the experiments reflected the effect of the genes that 
were being knocked down. To investigate the cell’s gene 
expression profiles, we compared cells that were treated 
with siRNA and negative controls which consisted of 
cell that were transfected with negative control siRNA 
and untreated cells. This way we could confirm, through 
microarray analysis, the effect of the transfection process 
and the RNAi experiments.
FIGURE 2. Gene expression levels for raf -1, mekk1 and mlk3 according to their respective RNAi 
treatment. The negative control in the graph plot depicts the expression level (assumed to be at 
100% expression level) of the genes being compared in the negative control samples
TABLE 1. Relative regulation values of raf1, mekk1 and mlk3 gene expression in the mitogen – activated protein kinase (MAPK) after 
RNAi treatment. r1 : raf1 RNAi; m1 : mekk1 RNAi; m11 : mlk3 RNAi; mix : raf1, mekk1 and mlk3 RNAi. All RNAi treatments 
were compared against respective negative control siRNA (raf1 – neg lo; mekk1 – neg lo; mlk3 – neg hi). No value indicates no 
significant change in gene regulation
TARGET 
GENE
RNAi TREATMENT (Gene expression level % ± standard deviation)
r1 m1 m11 Mix
raf1 40.18% ± 7.07 - - 47.02% ± 19.30
mekk1 - 38.00% ± 19.65 - 52.58% ± 15.72
mlk3 - - 40.66± 4.69 43.24% ± 20.51
TABLE 2. Mixed siRNA cocktail ratio optimization
siRNA dosage [Each siRNA has an average 
concentration of 450 ng / μL]
Gene expression knockdown levels (%)
raf1 mekk1 mlk3
20 μL
*(6.7 + 6.7 +6.7)
67.20% 50.95% 6.82%
40 μL
*(13.3 + 13.3 +13.3)
56.59% 38.05% -13.17%
60 μL
*(20+20+20)
40.94% 49.46% -79.20%
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MICROARRAY AND DATA ANALYSIS
To investigate the effects of the RNAi experiments to 
the cells, we carried out cDNA microarray and produced 
gene expression profiles for each treatment in biological 
triplicates. Based on cell morphology observations, we 
suspected that certain pathways related to cell death must 
have been activated, so we decided to look at any group 
of genes that were involved in pathways such as apoptosis 
or necrosis. We carried out data analysis of the microarray 
expression profiles using the Genespring GX 11.5 
(Agilent©). We applied the RMA summarization algorithm 
to normalize the hybridization signals and set the baseline 
to the mean of the signal intensities to allow us to observe 
up and down regulation of genes between samples. We 
observed comparisons between treated samples, negative 
controls and untreated controls. 
 A list of genes from biological pathways which are 
involved in cell proliferation and cell death was generated 
to allow us to see the differential gene expression profiles 
of the experiments. All data was filtered and processed 
with coefficient of variance <50% between probe signal 
triplicates and significance of differential expression 
between different samples set at p-value <0.05. To increase 
statistical power and accuracy, we applied the Benjamin-
Hochberg p-value correction algorithm to the filtered data 
set. Expression levels for raf1, mekk1 and mlk3 genes were 
consistently the same in the negative control siRNA and 
untreated cell controls. They only displayed knockdowns 
whenever the specific siRNAs were transfected into the 
cells. This reaffirms the specificity of the treatment in 
particular to gene expression knockdown. The effects of 
the siRNA transfection however revealed activation of 
the apoptosis pathway. When we compared the different 
treatments to their matching negative control siRNA, we 
managed to filter out different gene expression profile 
patterns which were partially unique to each respective 
treatment (Table 3). 
 We primarily focused on the MAPK signaling pathway 
to distinguish differences between the different RNAi 
treatment. In general, each RNAi experiment produced 
an immune response which consists of the p53, apoptosis, 
toll-like receptor and the natural killer mediated toxicity 
pathways. Membrane proteins which are involved in 
the MAPK signaling pathways were also affected. These 
included the transforming growth factor β receptors, 
calcium channel proteins and fibroblast growth factors 
(Kingsley 1994). These proteins are important in growth 
and survival of the cells, however they were mostly down 
regulated in each of the RNAi treatments except for the 
mlk3 RNAi. This may indicate that when mlk3 is down 
regulated, alternate pathways are activated to maintain 
survival for the cells although we could not successfully 
identify the genes involved. We also observed that mekk1 
RNAi had activated the mek5 gene, which plays a major 
role in the big MAPK signaling pathway (English et al. 
1999). This discovery also indicated an alternate pathway 
supporting the cell’s capability to survive. Raf1 RNAi 
exhibited up regulation of the atf2 gene, which is involved 
in inducing apoptosis, validating its potential in killing 
cancer cells (Maekawa et al. 2007). When we analyzed 
the mix RNAi treatment, we saw down regulation of 
raf1, mekk1 and mlk3 genes but none of the alternate 
pathways which were detected in the single target RNAi 
experiments were activated. We did observe up regulation 
of the hspa1l gene, a component of the heat shock proteins 
which repairs damaged proteins and increase survivability 
of cells (Giuliano et al. 2011). The multiple target RNAi 
blockade had apparently stopped supporting alternate 
pathways from becoming activated but instead activated 
the heat shock response instead in retaliation to the stress 
imposed by the RNAi blockade. However, due to down 
regulation of important membrane proteins stated before, 
the cell appeared to have continued on with apoptosis.
 Gantier et al. (2010) has postulated on the relevance 
of the immune response being present during RNAi 
knockdown in order to properly treat cancers. Although 
we did not design a special siRNA with bi-functional 
properties, we suspect that the viral protein envelope we 
had used as the transfection reagent may have played a part 
in the immunostimulatory aspect. The apoptosis pathway 
has been up regulated at multiple points and the U937 
cells have begun entering their programmed cell death, 
as shown in Figure 3. The results of our work suggested 
that by using the viral protein envelope as the transfection 
reagent for the specific siRNA, we might be able to produce 
a similar effect to immunostimulatory siRNAs. This could 
TABLE 3. Relative regulation values of raf1, mekk1 and mlk3 gene expression in the mitogen – activated protein kinase 
(MAPK) after RNAi treatment. r1 : raf1 RNAi; m1 : mekk1 RNAi; m11 : mlk3 RNAi; mix : raf1, mekk1 and mlk3 RNAi; 
neg lo : negative control lo GC RNAi; neg hi; negative control hi GC RNAi. All RNAi treatments were compared against 
untreated cell samples. Positive regulation indicates relative up regulation and negative regulation indicates relative down 
regulation of gene expression in comparison to the same gene in untreated samples. 
No value indicates no significant change in gene regulation
TARGET 
GENE
RNAi treatment (gene expression regulation value; Benjamin-Hochberg corrected p-value)
r1 m1 m11 mix neg lo neg hi
raf1 -1.98; 0.006 - - -1.44; 0.013 - -
mekk1 - -2.27; 0.014 - -1.78; 0.009 - -
mlk3 +1.37; 0.003 - - - +1.42; 0.001 +1.51; 0.005
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be an avenue worth exploring as it could present a way of 
delivering the siRNAs while inducing immunostimulatory 
signals as it travels in in vivo samples. Transfection of 
specific siRNA targeting raf1, mekk1 and mlk3 in the 
MAPK pathway using viral protein envelopes may have the 
capability to produce immunostimulatory RNAi effects 
in AML cells. Multiple target RNAi can potentially block 
the MAPK pathway and cause cell death in cancer cells, 
specifically the AML cells. 
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